ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1351

Development, Implementation, and Usability Testing of a New Rheumatoid Arthritis Patient-Reported Outcomes EHR-based Dashboard: A Mixed-Method Study

Cammie Young1, Anna Montgomery2, Catherine Nasrallah3, Lindsay Jacobsohn4, Jennifer Barton5, Sara Murray4, Jinoos Yazdany6 and Gabriela Schmajuk7, 1University of California San Francisco, San Francisco, CA, 2University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, 3UCSF, San Francisco, 4University of California, San Francisco, San Francisco, CA, 5VA Portland Health Care System/OHSU, Portland, OR, 6UCSF, San Francisco, CA, 7UCSF / SFVA, San Francisco, CA

Meeting: ACR Convergence 2022

Keywords: informatics, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Shared decision making is a key component of a treat-to-target approach for the treatment of rheumatoid arthritis (RA). We created an EHR tool that displays patient-reported outcomes (PROs) on a dashboard for use during RA clinical visits to support shared decision making. We evaluated patient and clinician perspectives regarding incorporation of the dashboard into a clinical visit.

Methods: The dashboard was developed using a human-centered design approach with input from patients and clinicians (Figure 1). It incorporates historical and real-time EHR data to display trajectories of disease activity, functional status, pain scores, and medication use and recent labs (Figure 2). The dashboard was implemented at a university rheumatology clinic (Epic EHR), launching via Salesforce automatically when a patient’s chart is opened at the start of a visit. As a part of an ongoing pragmatic trial, patient and clinicians who used the dashboard between August 2021 and May 2022 were invited to complete a survey regarding its features, usability, and suggestions for improvement. For a subset of participants, patient and clinician responses from the same encounter were directly compared. A focus group of clinicians was also conducted to assess perceptions of the dashboard. Open-ended survey questions and focus group transcripts were analyzed thematically using grounded theory.

Results: 50 unique patient surveys and 47 surveys from 4 clinicians were completed. Most patients were female (88%), mean age was 61, 46% were self-reported non-Hispanic white, and mean (SD) CDAI score was 19.7 (10.7). 3 of 4 clinicians were physicians; one was a nurse practitioner (NP). Nearly all (92.0%) patients were interested in seeing the dashboard at a future visit, reporting that it helped to visualize their disease activity and facilitated communication with their clinician on disease progression and treatment plans. Several patients requested that the dashboard be accessible via the health portals for sharing with family and other clinicians.

32 patients and their treating clinician completed surveys related to the same visit: 72% of patient-clinician dyads agreed that the dashboard increased patient understanding of their medications, 59% agreed that the dashboard improved communication, and 81% of dyads recommended the dashboard for use in future visits (Table 1). During a focus group (N=5, including attendings, fellows, and an NP), 2 main challenges emerged: 1) missing historical data from incomplete PRO collection in-person or during virtual visits, resulting in a less helpful visualization, and 2) time constraints to discuss PROs during visits. Interestingly, more experienced clinicians were more comfortable incorporating PRO collection and discussion using the dashboard.

Conclusion: A patient-facing, EHR-based dashboard that displays PROs during RA clinical visits was well-accepted by both patients and clinicians. An ongoing pragmatic trial will assess whether use of the dashboard systematically improves patient satisfaction, self-efficacy, and patient-reported outcomes.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: C. Young, None; A. Montgomery, None; C. Nasrallah, None; L. Jacobsohn, None; J. Barton, None; S. Murray, None; J. Yazdany, AstraZeneca, Gilead, Bristol-Myers Squibb(BMS), Aurinia, Astra Zeneca, Pfizer; G. Schmajuk, None.

To cite this abstract in AMA style:

Young C, Montgomery A, Nasrallah C, Jacobsohn L, Barton J, Murray S, Yazdany J, Schmajuk G. Development, Implementation, and Usability Testing of a New Rheumatoid Arthritis Patient-Reported Outcomes EHR-based Dashboard: A Mixed-Method Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/development-implementation-and-usability-testing-of-a-new-rheumatoid-arthritis-patient-reported-outcomes-ehr-based-dashboard-a-mixed-method-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-implementation-and-usability-testing-of-a-new-rheumatoid-arthritis-patient-reported-outcomes-ehr-based-dashboard-a-mixed-method-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology